Biomarkers and Surrogate Endpoints for Normal-tissue Effects of Radiation Therapy: The Importance of Dose-volume Effects

• Type of Material: Article
• Authors: Søren M. Bentzen, University of Wisconsin; Matthew Parliament, University of Alberta; Joseph O. Deasy, Washington University; Adam Dicker, Radiat Therapy Oncol Grp; Walter Curran, Emory University; Jacqueline P. Williams, University of Rochester; Barry S. Rosenstein, New York University
• Language: English
• Date: 2010-01-01
• Publisher: Elsevier
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2010 Elsevier Inc. All rights reserved.
• Final Published Version (URL): http://dx.doi.org/10.1016/j.ijrobp.2009.08.076
• Title of Journal or Parent Work: International Journal of Radiation Oncology - Biology - Physics
• ISSN: 0360-3016
• Volume: 76
• Issue: 3
• Start Page: S145
• End Page: S150
• Grant/Funding Information: This work was funded in part by the Varian Visiting Professorship Grant to the Radiation Therapy Oncology Group and with Federal funds from the United States Department of Health and Human Services under Grant Number CA21661, CA 37422 and CA32115.; The authors acknowledge support by Alberta Cancer Research Institute Operating Grant #22175 (MP), Department of the Army grant PC074201, W81XWH-08-1-0529 and American Cancer Society Research Scholar Grant RSGT-05-200-01-CCE (BSR); and grants 5 U19 AI067733-04 and 1 RC1 AI081244-01 (JPW); NCI grant CA85181 (JOD).
• Keywords: MOLECULAR MARKERS; Life Sciences & Biomedicine; Radiology, Nuclear Medicine & Medical Imaging; Single nucleotide polymorphisms; Oncology; GENOME-WIDE ASSOCIATION; TGF-BETA-1; Science & Technology; PREDICTIVE ASSAYS; Biomarkers; Predictive factors; RISK; Surrogate endpoints; CELL LUNG-CANCER; POSTMASTECTOMY RADIOTHERAPY; TOXICITY; Toxicity; Normal tissue effects; RADIOSENSITIVITY; Radiogenomics; Dose distribution; PNEUMONITIS
• Research Categories: Health Sciences, Radiology; Health Sciences, Oncology

Abstract

Biomarkers are of interest for predicting or monitoring normal tissue toxicity of radiation therapy. Advances in molecular radiobiology provide novel leads in the search for normal tissue biomarkers with sufficient sensitivity and specificity to become clinically useful. This article reviews examples of studies of biomarkers as predictive markers, as response markers, or as surrogate endpoints for radiation side effects. Single nucleotide polymorphisms are briefly discussed in the context of candidate gene and genomewide association studies. The importance of adjusting for radiation dose distribution in normal tissue biomarker studies is underlined. Finally, research priorities in this field are identified and discussed.